Business Context and Reporting Period
Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company focused on developing pharmaceutical products for medical and aesthetic skin conditions. The company operates as a single segment and has not yet generated revenue. This Form 10-Q covers the quarterly period ended March 31, 2025.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,303,587) | $(3,134,262) |
| Net Loss Per Share (Basic & Diluted) | $(0.45) | $(7.06) |
| Cash and Cash Equivalents (End of Period) | $9,719,268 | $4,733,681 |
| Accumulated Deficit | $(67,978,926) | $(56,522,140) |
| Net Cash Used in Operating Activities | $(1,934,066) | $(2,704,454) |
| Net Cash Provided by Financing Activities | $8,491,764 | $0 |
| Total Liabilities | $2,703,785 | $1,972,794 |
Material Changes vs. Prior Period
- Reduced Operating Expenses: Total operating expenses decreased by $863,757 (27%) to $2.34 million. This was driven by a $319,600 decrease in R&D expenses (due to the completion of enrollment in the STAR-1 trial and reduced stock-based compensation) and a $544,157 decrease in G&A expenses (due to reduced stock-based compensation and audit fees).
- Significant Capital Raise: The company raised approximately $8.5 million in net proceeds during Q1 2025 through a January PIPE financing ($2.3 million) and a March warrant inducement exercise ($5.8 million). This contrasts with zero financing proceeds in Q1 2024.
- Share Count Expansion: Outstanding common shares increased from 2.52 million at year-end 2024 to 6.03 million at March 31, 2025, due to equity issuances and warrant exercises.
- Improved Liquidity: Cash balances more than tripled from $3.16 million at December 31, 2024, to $9.72 million at March 31, 2025.
Outlook, Risks, and Management Commentary
- Clinical Milestone: In March 2025, the company announced positive topline results for the XYNGARI Phase 3 STAR-1 clinical trial for acne, meeting all co-primary endpoints. A second Phase 3 trial (STAR-2) is planned to begin by the end of 2025.
- Liquidity and Going Concern: Management expects current cash resources to fund operations into the first quarter of 2026. The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern for one year following the issuance date, necessitating future capital raises.
- Supply Chain Risk: The company relies on an exclusive supply agreement with a Russian entity for Spongilla raw material. While current inventory is sufficient for two Phase 3 studies, future sanctions or export controls could disrupt supply.
- Listing Compliance: Subsequent to the quarter end, Nasdaq notified the company of non-compliance with the minimum stockholders' equity requirement. The company has until May 9, 2025, to regain compliance or submit a plan.
- Collaboration: A clinical trial collaboration was entered into with Revance Therapeutics to evaluate XYNGARI combined with Daxxify for hyperhidrosis.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2026" funding estimate given the high burn rate and potential for accelerated spending on the STAR-2 trial.
- Supply Chain Resilience: Assess the specific risks associated with the Russian raw material supplier and the sufficiency of current inventory levels against potential new sanctions.
- Nasdaq Compliance: Monitor the company's progress in meeting the minimum stockholders' equity requirement to avoid delisting.
- Dilution Impact: Review the terms of the 12.4 million outstanding warrants and the 4.2 million shares held in abeyance, which represent significant potential dilution.
- STAR-2 Trial Timeline: Confirm the start date and funding requirements for the mandatory second Phase 3 trial required by the FDA.